Association of polymorphisms of FAS-1377, FAS-670, and FASL-844 genes with risk factors for cutaneous malignant melanoma

Cancer Journal

Volumn 13, Issue 4, 2007, Pages 226-228

  Gaddipati, Himabindu ^a   Herlyn, Meenhard ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FAS ANTIGEN; FAS LIGAND; FASLG PROTEIN, HUMAN; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CASE CONTROL STUDY; CELL DEATH; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DNA POLYMORPHISM; EYE COLOR; FAS 1377 GENE; FAS 670 GENE; FASL 844 GENE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAIR COLOR; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; NOTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCIENTIFIC LITERATURE; SIGNAL TRANSDUCTION; SUN EXPOSURE; TREATMENT OUTCOME; UTERINE CERVIX CANCER; ADULT; FEMALE; GENETIC POLYMORPHISM; GENETICS; MALE; MIDDLE AGED; RISK FACTOR; SKIN TUMOR;

ADULT; ANTIGENS, CD95; FAS LIGAND PROTEIN; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SKIN NEOPLASMS;

EID: 35748942608     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31813fffdd     Document Type: Note

References (19)

1. Zhang H, Sun X-F, Synnerstad I, et al. Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis. Cancer J. 2007;13:233-237.
2. Lai HC, Lin WY, Lin YW, et al. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. Gynecol Oncol. 2005;99:113-118.
3. Zhang X, Miao X, Sun T, et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet. 2005;2:479-484.
4. Zhang B, Sun T, Xue L, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007;28:1067-1063.
5. Sun T, Miao X, Zhang X, et al. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004 Jul 7;96:1030-1036.
6. Yang S, Miao XP, Zhang XM, et al. Genetic polymorphisms of apop-tosis-associated genes FAS and FASL and risk of colorectal cancer. Zhonghua Yi Xue Za Zhi. 2005;85:2132-2135 (in Chinese).
7. Elyassaki W, Wu S. ING3 promotes UV-induced apoptosis via Fas/ caspase-8 pathway in melanoma cells. J Biol Chem. 2006;281:11887-11893.
8. Ivanov VN, Ronai Z. p38 protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-κB activity and Fas expression. Oncogene. 2000;19:3003-3012.
9. Melzani G, Bugari G, Parrinello G, et al. Evaluation of soluble Fas ligand as a serological marker for melanoma. Dermatology. 2002;205: 111-115.
10. Neuber K. Eidam B. Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival. Onkologie. 2006;29:361-365.
11. Li C, Larson D, Zhang Z, Liu Z, et al. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics. 2006;16:253-263.
12. Park SH, Choi JEm Kim EJ, et al. Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer. 2006;54:303-308.
13. Sun T, Zhou Y, Li H, et al. FASL-844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 2005;202:967-974.
14. Bullani RR, Wehrli P, Viard-Leveugle I. Frequent downregulation of Fas (CD95) expression and function in melanoma: frequent downregulation of Fas (CD95) expression and function in melanoma. Melanoma Res. 2002;12:263-270.
15. Urquhart JL, Meech SJ, Marr DG, et al. Regulation of Fas-mediated apoptosis by N-ras in melanoma. J Invest Dermatol. 2002;119:556-561.
16. Kamei T, Inui M, Nakase M, et al. Experimental therapy using interferonγ and anti-Fas antibody against oral malignant melanoma cells. Melanoma Res. 2005;15:393-400.
17. Hall CL, Yao M, Hill LL, et al. Essential role for hematopoietic Fas ligand (FasL) in the suppression of melanoma lung metastasis revealed in bone marrow chimeric mice. Clin Exp Metastasis. 2004;21:251-256.
18. Eberle J, Fecker LF, Hossini AM, et al. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. Oncogene. 2003;22:9131-9141.
19. Fecker LF, Geilen CC, Hossini AM, et al. Selective induction of apoptosis in melanoma cells by tyrosinase promoter-controlled CD95 ligand overexpression. J Invest Dermatol. 2005;124:221-228.